UCLA Initiates a NIDA-Supported Phase 1b Study With Ibudilast in Methamphetamine-Dependent Volunteers

SAN DIEGO, Sept. 27, 2010 (GLOBE NEWSWIRE) — MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA’s approval to proceed with an initial trial of the company’s neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy [...] http://bit.ly/afyIy0